Abbott Laboratories (ETR: ABL)
Germany
· Delayed Price · Currency is EUR | Market Cap | 191.26B |
| Revenue (ttm) | 36.96B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.95 |
| PE Ratio | 37.14 |
| Forward PE | n/a |
| Dividend | 2.10 (1.90%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 161 |
| Average Volume | 174 |
| Open | 110.40 |
| Previous Close | 109.38 |
| Day's Range | 110.36 - 111.22 |
| 52-Week Range | 90.00 - 114.14 |
| Beta | 0.72 |
| RSI | 49.95 |
| Earnings Date | Jan 22, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, Abbott Laboratories's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.70 billion, a decrease of -17.44%.
Financial numbers in USD Financial StatementsNews
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Long-term possibilities in healthcare are unbelievable, says Jim Cramer
'Mad Money' host Jim Cramer looks at several healthcare stocks and shares his perspective on their trajectory in 2025.
We are probably one of the most diversified healthcare companies now, says Abbott Labs CEO Robert Ford
Abbott Labs Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk its medical equipment offerings, the infant formula litigation, and more.
Abbott Laboratories Q4 2024 Earnings Preview
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. See why I maintain my buy rating on ABT stock.
Abbott Laboratories: An Exploration into Its Intrinsic Value
Abbott Laboratories: An Exploration into Its Intrinsic Value
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.
How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE: ABT) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short , which is 0.7% of all regu...
My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is...
Highest Quality Dividend Kings For 2025
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation ...
The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value
The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value
DexCom, Abbott Agree to Settlement in Patent Litigation
The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other par...
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Abbott Laboratories Unveils Groundbreaking Leadless Pacemaker Technology
Abbott Laboratories Unveils Groundbreaking Leadless Pacemaker Technology
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural condu...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
Abbott Laboratories raises dividend by 7.3% to $0.59
Abbott Laboratories (ABT) increases quarterly dividend by 7.3% to $0.59/share, marking 53rd consecutive year of dividend growth.
Abbott Laboratories Increases Quarterly Dividend for 53rd Consecutive Year
Abbott Laboratories Increases Quarterly Dividend for 53rd Consecutive Year
Abbott Increases Quarterly Dividend for 53rd Consecutive Year
Dividend increased by 7.3% Quarterly dividend payout has increased more than 60% since 2020 404th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 13, 2024 /PRNew...
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Thursday. The Dow traded down 0.46% to 43,947.18 while the NASDAQ fell 0.38% to 19,957.81. The...
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
U.S. stocks traded lower midway through trading, with the Dow Jones index falling by 0.2% on Thursday. The Dow traded down 0.18% to 44,067.70 while the NASDAQ fell 0.33% to 19,969.33. The S&P 500 also...
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Thursday. Following the market opening Thursday, the Dow traded down 0.01% to 44,142.13 while the...
Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them
On CNBC's “ Mad Money Lightning Round ,” Jim Cramer said Occidental Petroleum (NYSE: OXY) is one of his “least favorite oils.” On Monday, UBS analyst Josh Silverstein maintained Occidental Petroleum ...
Lightning Round: Abbott Labs' legal trouble is largely behind it, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Occidental Petroleum, Cooper Companies, Energy Transfer, Eli Lilly, Abbott Labs, Kinder Morgan, and more.